MLBPA releases its statement on HGH testing

Leave a comment

HGH.jpgThe entire statement can be read here.  The relevant part in my mind:

This week, a British rugby player was suspended as a result of a
reported positive blood test for HGH.   This development warrants
investigation and scrutiny; we already have conferred with our experts
on this matter, and with the Commissioner’s Office, and we immediately
began gathering additional information.  However, a report of a single
uncontested positive does not scientifically validate a drug test.  As
press reports have suggested, there remains substantial debate in the
testing community about the scientific validity of blood testing for
HGH.   And, as we understand it, even those who vouch for the
scientific validity of this test acknowledge that it can detect use
only 18-36 hours prior to collection.

Putting these important issues aside, inherent in blood testing of
athletes are concerns of health, safety, fairness and competition not
associated with urine testing.  We have conferred initially with the
Commissioner’s Office about this reported positive test, as we do
regarding any development in this area.  We look forward to continuing
to jointly explore all questions associated with this testing — its
scientific validity, its effectiveness in deterring use, its
availability and the significant complications associated with blood
testing, among others.

This pretty much tracks my thinking from yesterday.  Jumping in with both feet now, based on the rugby player’s test would be an exercise in PR, not a reasoned implementation of expanded PED testing.

To the extent there’s a line in the sand here, it’s that the union seems unwilling to accept blood testing of any kind, instead wanting to wait for a urine test.  I know that no urine test exists for HGH. The key question here is whether that’s the case simply because one hasn’t been developed yet or if there is some physiological reason why there can never be a urine test (Rays Fan — any insight here?).

Either way, I expect someone to spin the blood/urine test as the union being intransigent.  To those who do, I ask whether or not their employer tests their blood on a routine basis, and if not, how they would feel about it if they suddenly began to do so.

Report: Nathan Eovaldi drawing interest from at least nine teams

Nathan Eovaldi
Getty Images
1 Comment

Former Red Sox right-hander Nathan Eovaldi is up for grabs this offseason, and Nick Cafardo of the Boston Globe says that as many as nine suitors are interested in bringing the righty aboard. While the Red Sox are eager to retain Eovaldi’s services after his lights-out performance during their recent postseason run, they’ll have to contend with the Brewers, Phillies, Braves, White Sox, Padres, Blue Jays, Giants, and Angels — all of whom are reportedly positioned to offer something for the starter this winter.

It wasn’t all smooth sailing for the 28-year-old in 2018, however. After losing his 2017 season to Tommy John surgery, he underwent an additional procedure to remove loose bodies from his right elbow in March and didn’t make his first appearance until the end of May. He was flipped for lefty reliever Jalen Beeks just prior to the trade deadline and finished his season with a combined 6-7 record in 21 starts, a 3.81 ERA, 1.6 BB/9, and 8.2 SO/9 through 111 innings.

Despite his numerous health issues over the last few years, Eovaldi raised his stock in October after becoming a major contributor during the Red Sox’ championship run. He contributed two quality starts in the ALDS and ALCS and returned in Games 1-3 of the World Series with three lights-out performances in relief — including a six-inning effort in the 18-inning marathon that was Game 3.

A frontrunner has yet to emerge for the righty this offseason, but Cafardo points out that the nine teams listed so far might just be the tip of the iceberg. Still, he won’t be the most sought-after starter on the market, as former Diamondbacks southpaw Patrick Corbin is expected to command an even bigger payday following his career-best 6.0-fWAR performance in 2018.